Evidence map›Paper›PMID 36558190›Full record

ArticleMolecules (Basel, Switzerland)2022

Pro-Inflammatory Interactions of Dolutegravir with Human Neutrophils in an In Vitro Study.

Annette J Theron, Ronald Anderson, Morris Madzime, Theresa M Rossouw, Helen C Steel, Pieter W A Meyer, Moloko C Cholo, Luyanda L I Kwofie, Charles Feldman, Gregory R Tintinger

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Annette J TheronDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa.
Ronald AndersonDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa.ORCID 0000-0002-5925-6452
Morris MadzimeDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa.
Theresa M RossouwDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa.ORCID 0000-0003-4066-922X
Helen C SteelDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa.ORCID 0000-0001-5899-4472
Pieter W A MeyerDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa.ORCID 0000-0002-7318-1055
Moloko C CholoDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa.
Luyanda L I KwofieDepartment of Immunology, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa.
Charles FeldmanDepartment of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
Gregory R TintingerDepartment of Internal Medicine, Steve Biko Academic Hospital, Faculty of Health Sciences, University of Pretoria, Pretoria 0002, South Africa.
University of Pretoria · ZANational Health Laboratory Service · ZASteve Biko Hospital · ZAUniversity of the Witwatersrand · ZA

Funding

National Health Laboratory Research Trust of South Africa 004 94713
6 · The paper itself

Abstract

There is increasing awareness of an association between the uptake of the HIV integrase inhibitor, dolutegravir, in first-line antiretroviral regimens with unusual weight gain and development of the metabolic syndrome, particularly in African women. Although seemingly unexplored, the development of systemic inflammation linked to the putative pro-inflammatory activity of dolutegravir represents a plausible pathophysiological mechanism of this unusual weight gain. This possibility was explored in the current study undertaken to investigate the effects of dolutegravir (2.5−20 μg/mL) on several pro-inflammatory activities of neutrophils isolated from the blood of healthy, adult humans. These activities included the generation of reactive oxygen species (ROS), degranulation (elastase release) and alterations in the concentrations of cytosolic Ca2+ using chemiluminescence, spectrophotometric and fluorimetric procedures, respectively. Exposure of neutrophils to dolutegravir alone resulted in the abrupt, dose-related, and significant (p < 0.0039−p < 0.0022) generation of ROS that was attenuated by the inclusion of the Ca2+-chelating agent, EGTA, or inhibitors of NADPH oxidase (diphenyleneiodonium chloride, DPI), phospholipase C (U733122), myeloperoxidase (sodium azide) and phosphoinositol-3-kinase (wortmannin). In addition, exposure to dolutegravir augmented the release of elastase by stimulus-activated neutrophils. These pro-inflammatory effects of dolutegravir on neutrophils were associated with significant, rapid, and sustained increases in the concentrations of cytosolic Ca2+ that appeared to originate from the extracellular compartment, seemingly consistent with an ionophore-like property of dolutegravir. These findings are preliminary and necessitate verification in the clinical setting of HIV infection. Nevertheless, given the complex link between inflammation and obesity, these pro-inflammatory interactions of dolutegravir with neutrophils may contribute to unexplained weight gain, possibly via the development of insulin resistance.

Indexed as

HIV InfectionsHIV Integrase InhibitorsAdultDolutegravirFemaleHeterocyclic Compounds, 3-RingHumansInflammationNeutrophilsPancreatic ElastaseReactive Oxygen SpeciesDolutegravirHeterocyclic Compounds, 3-RingHIV Integrase InhibitorsPancreatic ElastaseReactive Oxygen Speciescytosolic calciumelastaseHIVionophorepro-inflammatory activity

Identifiers

PMID36558190
PMCPMC9780875
OpenAlexW4312194468

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.